<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Myeloid-derived suppressor cells (MDSCs) are a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> family of myeloid cells that suppress T cell immunity in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-bearing hosts </plain></SENT>
<SENT sid="1" pm="."><plain>In patients with <z:hpo ids='HP_0003003'>colon cancer</z:hpo>, MDSCs have recently been described as Lin(-/low)HLA-DR(-)CD11b(+)CD33(+) cells correlating with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stage, <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> and chemotherapy response </plain></SENT>
<SENT sid="2" pm="."><plain>To learn in more detail the dynamic change and clinical relevance of circulating and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-infiltrating Lin(-/low)HLA-DR(-)CD11b(+)CD33(+) MDSC in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, we harvested the blood from 64 patients with varying stage of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and matched paraneoplastic tissues from 5 patients with advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, subjected them to multicolor flow cytometric analysis of percentage, absolute number and phenotype of MDSC and finally characterized their immunosuppressive functions </plain></SENT>
<SENT sid="3" pm="."><plain>Our results demonstrate that peripheral blood from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients contains markedly increased percentage and absolute number of Lin(-/low)HLA-DR(-)CD11b(+)CD33(+) MDSCs compared with healthy individuals, and this increase is closely correlated with clinical <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stage and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">tumor metastasis</z:e> but not <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> size and serum concentrations of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> biomarker </plain></SENT>
<SENT sid="4" pm="."><plain>A similar increase of MDSCs was also observed in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissues </plain></SENT>
<SENT sid="5" pm="."><plain>Phenotyping MDSCs shows that they express high CD13 and CD39, low CD115, CD117, CD124 and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-L1, and devoid of CD14, CD15 and CD66b, reminiscent of precursor myeloid cells </plain></SENT>
<SENT sid="6" pm="."><plain>MDSCs from <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients but not healthy donors have the immunosuppressive activity and were able to inhibit in vitro autologous T-cell proliferation </plain></SENT>
<SENT sid="7" pm="."><plain>Collectively, this study substantiates the presence of increased immunosuppressive circulating and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-resident Lin(-/low)HLA-DR(-)CD11b(+)CD33(+) MDSCs in patients with <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> correlating with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stage and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>, and suggests that pharmacologic blockade of MDSCs should be considered in future clinical trials </plain></SENT>
</text></document>